Maximum Per Day Infusion Dose of Furosemide
The maximum daily dose of intravenous furosemide is 240 mg in the first 24 hours for acute heart failure, with a maximum infusion rate of 4 mg/min, though higher doses up to 600 mg/day may be used in severe edematous states with careful monitoring. 1, 2
Standard Maximum Dosing by Clinical Context
Acute Heart Failure
- Total furosemide dose should remain <100 mg in the first 6 hours and <240 mg during the first 24 hours 1
- Initial IV bolus: 20-40 mg over 1-2 minutes, with higher doses (up to 80 mg) for patients already on chronic oral diuretics 1
- Continuous infusion: 5-10 mg/hour, with maximum infusion rates not exceeding 4 mg/min 1
- Doses of 250 mg and above must be given by infusion over 4 hours to prevent ototoxicity 1
Cirrhosis with Ascites
- Maximum oral dose: 160 mg/day, typically combined with spironolactone 3, 1
- Initial dose: 40 mg/day, increased every 2-3 days up to 160 mg/day 3
- Exceeding 160 mg/day indicates diuretic resistance requiring alternative strategies (large volume paracentesis) rather than further dose escalation 1
- High doses are associated with severe electrolyte disturbance and metabolic alkalosis 3
Severe Edematous States
- The FDA label indicates doses may be carefully titrated up to 600 mg/day in severe edematous states 2
- In refractory cardiac failure, doses up to 700 mg/day (mean maintenance) have been used successfully, with peak doses reaching 8 g/day in one case report 4
- However, in chronic renal insufficiency, maximal response is attained with single IV doses of 120-160 mg, with no benefit from larger single doses 5
Critical Infusion Rate Considerations
- Infusions must be administered over 5-30 minutes to avoid hearing loss 1
- Maximum infusion rate: 4 mg/min 1
- Rapid IV administration increases risk of ototoxicity, particularly at high doses 1, 2
Mandatory Monitoring Requirements
During High-Dose Infusion
- Urine output: hourly monitoring 1
- Blood pressure: every 15-30 minutes in first 2 hours 1
- Electrolytes (sodium, potassium): within 6-24 hours 1
- Renal function: within 24 hours 1
- Bladder catheter placement recommended for rapid assessment of treatment response 1
Ongoing Monitoring
- Daily weights targeting 0.5-1.0 kg loss per day 1
- Electrolytes every 3-7 days during initial titration 1
- Serum creatinine and sodium concentration, particularly during first weeks 1
Absolute Contraindications to Dose Escalation
Stop furosemide immediately if any of the following develop: 1
- Severe hyponatremia (serum sodium <120-125 mmol/L)
- Severe hypokalemia (<3 mmol/L)
- Progressive renal failure or acute kidney injury
- Anuria
- Marked hypotension (SBP <90 mmHg without circulatory support)
- Worsening hepatic encephalopathy (in cirrhotic patients)
- Incapacitating muscle cramps
Management of Inadequate Response
Rather than escalating furosemide beyond 160-240 mg/day, consider combination therapy: 1
- Add thiazide diuretic (hydrochlorothiazide 25 mg orally)
- Add aldosterone antagonist (spironolactone 25-50 mg orally)
- Sequential nephron blockade is more effective than monotherapy escalation 1
Alternative Strategies
- In acute pulmonary edema: IV nitroglycerin is superior to high-dose furosemide alone 1
- In cirrhosis exceeding 160 mg/day: large volume paracentesis with albumin replacement 1
- In refractory cases: consider venovenous isolated ultrafiltration 1
Common Pitfalls to Avoid
- Do not administer furosemide to hypotensive patients expecting hemodynamic improvement—it worsens tissue perfusion and precipitates cardiogenic shock 1
- Do not exceed 6 mg/kg/day for periods longer than 1 week in pediatric patients 1
- Do not use furosemide to prevent or treat acute kidney injury—only for managing volume overload that complicates AKI 1
- Avoid evening doses causing nocturia and poor adherence 1
- Do not escalate beyond 80-160 mg daily without adding a second diuretic due to ceiling effect 1
Special Population Considerations
Pediatric Patients
- Maximum dose: 6 mg/kg/day 1
- Doses greater than 6 mg/kg/day not recommended for >1 week 1
- Monitor for nephrocalcinosis/nephrolithiasis, especially in premature infants 2
Elderly Patients
- Start at low end of dosing range due to decreased renal function 2
- More likely to experience toxic reactions due to impaired renal function 2